Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age

Seth Chekata Inzaule; Michael R. Jordan; Amandine Cournil; Marco Vitoria; Giovanni Ravasi; Fatim Cham; Linh Vi Le; Janet Dzangare; Ndapewa Hamunime; Nicholus Mutenda; Avelin Aghokeng; Annez Bissek; Serge Billong; Pontiano Kaleebu; Meg Doherty; Silvia Bertagnolio

doi:10.1097/QAD.0000000000002277

Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age

Seth Chekata Inzaule, Michael R. Jordan, Amandine Cournil, Marco Vitoria, Giovanni Ravasi, Fatim Cham, Linh Vi Le, Janet Dzangare, Ndapewa Hamunime, Nicholus Mutenda, Avelin Aghokeng, Annez Bissek, Serge Billong, Pontiano Kaleebu, Meg Doherty, Silvia Bertagnolio

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Use of dolutegravir-based first-line antiretroviral therapy (ART) in response to rising levels of pretreatment HIV drug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be limited, given safety concerns for birth defects in women of child-bearing potential. Pooled data from 11 nationally representative surveys show that NNRTI PDR in women is nearly twice that in men, exceeding 10% in 8 of 11 countries monitored, suggesting the urgent need for a non-NNRTI-based ART regimen in this population.

Original language	English (US)
Pages (from-to)	1797-1799
Number of pages	3
Journal	AIDS
Volume	33
Issue number	11
DOIs	https://doi.org/10.1097/QAD.0000000000002277
State	Published - Sep 1 2019

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Infectious Diseases

Access to Document

10.1097/QAD.0000000000002277

Fingerprint Dive into the research topics of 'Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age'. Together they form a unique fingerprint.

Cite this

Inzaule, S. C., Jordan, M. R., Cournil, A., Vitoria, M., Ravasi, G., Cham, F., Le, L. V., Dzangare, J., Hamunime, N., Mutenda, N., Aghokeng, A., Bissek, A., Billong, S., Kaleebu, P., Doherty, M., & Bertagnolio, S. (2019). Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age. AIDS, 33(11), 1797-1799. https://doi.org/10.1097/QAD.0000000000002277

Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age. / Inzaule, Seth Chekata; Jordan, Michael R.; Cournil, Amandine; Vitoria, Marco; Ravasi, Giovanni; Cham, Fatim; Le, Linh Vi; Dzangare, Janet; Hamunime, Ndapewa; Mutenda, Nicholus; Aghokeng, Avelin; Bissek, Annez; Billong, Serge; Kaleebu, Pontiano; Doherty, Meg; Bertagnolio, Silvia.

In: AIDS, Vol. 33, No. 11, 01.09.2019, p. 1797-1799.

Research output: Contribution to journal › Article › peer-review

Inzaule, SC, Jordan, MR, Cournil, A, Vitoria, M, Ravasi, G, Cham, F, Le, LV, Dzangare, J, Hamunime, N, Mutenda, N, Aghokeng, A, Bissek, A, Billong, S, Kaleebu, P, Doherty, M & Bertagnolio, S 2019, 'Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age', AIDS, vol. 33, no. 11, pp. 1797-1799. https://doi.org/10.1097/QAD.0000000000002277

Inzaule, Seth Chekata ; Jordan, Michael R. ; Cournil, Amandine ; Vitoria, Marco ; Ravasi, Giovanni ; Cham, Fatim ; Le, Linh Vi ; Dzangare, Janet ; Hamunime, Ndapewa ; Mutenda, Nicholus ; Aghokeng, Avelin ; Bissek, Annez ; Billong, Serge ; Kaleebu, Pontiano ; Doherty, Meg ; Bertagnolio, Silvia. / Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age. In: AIDS. 2019 ; Vol. 33, No. 11. pp. 1797-1799.

@article{0c1002c0ffb7489aaa5fae2915e8557a,

title = "Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age",

abstract = "Use of dolutegravir-based first-line antiretroviral therapy (ART) in response to rising levels of pretreatment HIV drug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be limited, given safety concerns for birth defects in women of child-bearing potential. Pooled data from 11 nationally representative surveys show that NNRTI PDR in women is nearly twice that in men, exceeding 10% in 8 of 11 countries monitored, suggesting the urgent need for a non-NNRTI-based ART regimen in this population.",

author = "Inzaule, {Seth Chekata} and Jordan, {Michael R.} and Amandine Cournil and Marco Vitoria and Giovanni Ravasi and Fatim Cham and Le, {Linh Vi} and Janet Dzangare and Ndapewa Hamunime and Nicholus Mutenda and Avelin Aghokeng and Annez Bissek and Serge Billong and Pontiano Kaleebu and Meg Doherty and Silvia Bertagnolio",

year = "2019",

month = sep,

day = "1",

doi = "10.1097/QAD.0000000000002277",

language = "English (US)",

volume = "33",

pages = "1797--1799",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "11",

}

TY - JOUR

T1 - Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age

AU - Inzaule, Seth Chekata

AU - Jordan, Michael R.

AU - Cournil, Amandine

AU - Vitoria, Marco

AU - Ravasi, Giovanni

AU - Cham, Fatim

AU - Le, Linh Vi

AU - Dzangare, Janet

AU - Hamunime, Ndapewa

AU - Mutenda, Nicholus

AU - Aghokeng, Avelin

AU - Bissek, Annez

AU - Billong, Serge

AU - Kaleebu, Pontiano

AU - Doherty, Meg

AU - Bertagnolio, Silvia

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Use of dolutegravir-based first-line antiretroviral therapy (ART) in response to rising levels of pretreatment HIV drug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be limited, given safety concerns for birth defects in women of child-bearing potential. Pooled data from 11 nationally representative surveys show that NNRTI PDR in women is nearly twice that in men, exceeding 10% in 8 of 11 countries monitored, suggesting the urgent need for a non-NNRTI-based ART regimen in this population.

AB - Use of dolutegravir-based first-line antiretroviral therapy (ART) in response to rising levels of pretreatment HIV drug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be limited, given safety concerns for birth defects in women of child-bearing potential. Pooled data from 11 nationally representative surveys show that NNRTI PDR in women is nearly twice that in men, exceeding 10% in 8 of 11 countries monitored, suggesting the urgent need for a non-NNRTI-based ART regimen in this population.

UR - http://www.scopus.com/inward/record.url?scp=85069914723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069914723&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000002277

DO - 10.1097/QAD.0000000000002277

M3 - Article

C2 - 31149946

AN - SCOPUS:85069914723

VL - 33

SP - 1797

EP - 1799

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 11

ER -

Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this